Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro

Molecular Cancer Therapeutics

Volumn 5, Issue 1, 2006, Pages 156-159

  Hostetler, Karl Y ^a   Rought, Steffney ^a   Aldern, Kathy A ^a   Trahan, Julissa ^a   Beadle, James R ^a   Corbeil, Jaques ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Université Laval   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; DRUG DERIVATIVE; PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOBLASTOMA PROTEIN; TETRAZOLIUM; ANTINEOPLASTIC AGENT; CYTOSINE; ESTER; PHOSPHONIC ACID DERIVATIVE;

ADENOVIRUS; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE S PHASE; CELL DIVISION; CELL PROLIFERATION; COWPOX VIRUS; CYTOMEGALOVIRUS; DNA VIRUS; DRUG MECHANISM; DRUG STRUCTURE; HELA CELL; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IN VITRO STUDY; INFECTION RISK; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SKIN FIBROBLAST; SMALLPOX VIRUS; UTERINE CERVIX CANCER; VACCINIA VIRUS; WART VIRUS; CELL CULTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; FEMALE; FIBROBLAST; PATHOLOGY; UTERINE CERVIX TUMOR; VIRUS INFECTION;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CYTOSINE; DRUG SCREENING ASSAYS, ANTITUMOR; ESTERS; FEMALE; FIBROBLASTS; HELA CELLS; HUMANS; PAPILLOMAVIRUS INFECTIONS; PHOSPHONIC ACIDS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 33644872203     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0200     Document Type: Article

References (20)

1. The studies of ocular complications of AIDS research group in collaboration with the AIDS Clinical Trials Group, Cidofovir (HPMPC) for the treatment of cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. Ann Intern Med 1997; 126:264-74.
2. Bray M, Martinez M, Smee DF, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 2000;181:10-9.
3. De Clercq E, Neyts J. Efficacy of (S)-1-(3-hydroxy-2-phosphonyl-methoxy-propyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol 1993;41:242-6.
4. Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogs cidofovir and adefovir. Clin Pharmacokinet 1999;36:127-43.
5. Beadle JR, Kini GD, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication, in vitro. Antimicrob Agents Chemother 2002;46:2381-6.
6. Kern ER, Hartline C, Harden E, et al. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002;46:991-5.
7. Hartline CB, Gustin KM, Wan WB, et al. Activity of ether lipid ester prodrugs of acyclic nucleoside phosphonates against adenovirus replication in vitro. J Infect Dis 2005;191:396-9.
8. Wan WB, Beadle JR, Hartline CB, et al. Comparison of the antiviral activity of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother 2004;49:656-62.
9. 14C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol 2003;63:678-81.
10. Ciesla SL, Winegarden KL, Trahan J, Aldern KA, Painter GR, Hostetler KY. Oral bioavailability and tissue distribution of radiolabeled alkoxyalkanol esters of cidofovir in mice. Antiviral Res 2003;59:163-71.
11. Abdulkarim B, Sabri S, Deutsch E, et al. Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002;21:2334-46.
12. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol Res 1998;10:523-31.
13. Andrei G, Snoeck R, Schols D, De Clercq E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res 2001; 12:397-408.
14. Johnson JA, Gangemi JD. Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]- cytosine. Antimicrob Agents Chemother 1999;43: 1198-205.
15. Snoeck R, Wellens W, Desloovere C, et al. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir. J Med Virol 1998;54:219-25.
16. Gerlier D, Thomasset N. Use of MTT colorimetric assay to measure cell activation. J Immunol Methods 1986;94:57-63.
17. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
18. Scheffner M, Werness BA, Hulbreghtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
19. Heck DV, Yee CL, Howley PM, Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 1992;89:4442-6.
20. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.